Abiopharma

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

New Form 8-K - HEALTHCARE SERVICES GROUP INC Filed: 2025-07-23 AccNo: 0000731012-25-000097 Size: 289 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

CareDx - CareDx to Report Second Quarter 2025 Financial Results

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

CareDx to Report Second Quarter 2025 Financial Results

Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim

Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim

New Form 6-K - PURPLE BIOTECH LTD. Filed: 2025-07-23 AccNo: 0001213900-25-066804 Size: 38 KB

Compugen - Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Inotiv - Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025

Castle Biosciences - FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Healthcare Services Group, Inc. - HCSG Reports Second Quarter Results